Coldstream Capital Management Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 19,240 shares of the biopharmaceutical company’s stock, valued at approximately $1,652,000.
Several other institutional investors and hedge funds have also modified their holdings of GILD. Arrowstreet Capital Limited Partnership grew its holdings in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after acquiring an additional 6,410,047 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Gilead Sciences by 124.8% during the 2nd quarter. AQR Capital Management LLC now owns 6,095,793 shares of the biopharmaceutical company’s stock valued at $375,562,000 after acquiring an additional 3,383,767 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Gilead Sciences by 14.8% in the third quarter. Bank of New York Mellon Corp now owns 15,421,436 shares of the biopharmaceutical company’s stock worth $951,350,000 after purchasing an additional 1,987,058 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its holdings in Gilead Sciences by 66.5% in the third quarter. Ensign Peak Advisors Inc now owns 4,484,769 shares of the biopharmaceutical company’s stock worth $276,665,000 after purchasing an additional 1,790,559 shares in the last quarter. 78.72% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the stock in a transaction on Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the sale, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.16% of the company’s stock.
Gilead Sciences Price Performance
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.17. The company had revenue of $7.39 billion for the quarter, compared to analyst estimates of $6.63 billion. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The business’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period last year, the business posted $0.69 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post 6.86 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Wednesday, March 15th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Tuesday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 3.88%. Gilead Sciences’s dividend payout ratio (DPR) is 82.19%.
Analyst Ratings Changes
A number of research firms have weighed in on GILD. Barclays boosted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 18th. Robert W. Baird upped their price objective on shares of Gilead Sciences from $69.00 to $80.00 in a research note on Friday, February 3rd. DZ Bank cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Friday, December 9th. Oppenheimer increased their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Thursday, December 1st. Finally, Bank of America reissued a “neutral” rating and set a $85.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 13th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $89.40.
Gilead Sciences Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.